2026-07-23 10:03:27 · Revision 1
Class 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged release 20mg, 30mg and 40…
Read full MHRA notice ↗Source: Medicines and Healthcare products Regulatory Agency (MHRA). Read the full notice, including its required actions and deadlines, before recording your response.